CUA Educational Content

Advancement in the management of Von Hippel Landau (VHL) Disease: A Comprehensive Educational Program on hypoxia-inducible factor-2 alpha inhibitor (HIF-2a)

Moderator: Simon Tanguay

Speakers: Shereen Ezzat & Maryam Soleimani

Objectives:

By participating in this learning program, healthcare providers can expect to:

  • Discuss the mechanism of action of HIF-2α inhibitors in suppressing tumor growth in VHL-related tumors.
  • Examine the clinical efficacy and safety profile of HIF-2α inhibitors and impact on clinical practice.
  • Explore strategies for early identification and management of side effects associated with HIF-2α inhibitors, based on evidence-based medicine and lessons learned from real-world experience.
Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.

-------------------------------------

This program has received financial support in the form of an educational grant from Merck.

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy